Rasshirenie ispol'zovaniya vnutrimatochnoy sistemy "Mirena": kriterii priemlemosti VOZ


Cite item

Full Text

Abstract

В 1994-1995 гг. Всемирной организацией здравоохранения был разработан новый подход к классификации приемлемости различных методов контрацепции, позволивший значительно укрепить и усовершенствовать доказательную базу для предоставления услуг и консультирования в области планирования семьи. Предлагаемые критерии приемлемости использования разных методов контрацепции базируются на доказательных данных, суммирующих результаты многих исследований, проводимых во всем мире. Это в свою очередь помогает медицинским работникам квалифицированно оценивать возможности клиентов/пациентов использовать тот или иной метод контрацепции, улучшает качество медицинской помощи с точки зрения ее безопасности, результативности и экономической эффективности.

About the authors

I S Savel'eva

ФГУ Научный центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной медицинской помощи, Москва

Zh A Gorodnicheva

ФГУ Научный центр акушерства, гинекологии и перинатологии Федерального агентства по высокотехнологичной медицинской помощи, Москва

References

  1. Cramer D.W et al. Tubal infertility and the intrauterine device. New England J Med 1985; 312: 941-7.
  2. Daling J.R et al. Primary tubal infertility in relation to the use of an intrauterine device. New England J Med 1985; 312: 937-41.
  3. Daling J.R et al. The intrauterine device and primary tubal infertility. New England J Med 1992; 326: 203-4.
  4. Delbarge W et al. Return to fertility in nulliparous and parous women after removal of the GyneFix intrauterine contraceptive system. Eur J Contracept Reprod Health Care 2002; 7: 24-30.
  5. Doll H, Vessey M, Painter R. Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception. BJOG. Int J Obstet Gynaecol 2001; 108: 304-14.
  6. Hubacher D et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. New England J Med 2001; 345: 561-7.
  7. Skjeldestad F.E, Bratt H. Return of fertility after use of IUDs (Nova-T, MLCu250 and MLCu375). Adv Contracept 1987; 3: 139-45.
  8. Urbach D.R et al. Association of perforation of the appendix with female tubal infertility. Am J Epidemiol 2001; 153: 566-71.
  9. Wilson J.C. A prospective New Zealand study of fertility after removal of copper intrauterine contraceptive devices for conception and because of complications: a four - year study. Am J Obstet & Gynecol 1989; 160: 391-6.
  10. Brenner P.F. A clinical trial of the Delta-T intrauterine device: immediate postpartum insertion. Contraception 1983; 28: 135-47.
  11. Chi I.C, Wilkens L, Rogers S. Expulsions in immediate postpartum insertions of Lippes Loop D and Copper T IUDs and their counterpart Delta devices--an epidemiological analysis. Contraception 1985; 32: 119-34.
  12. El-Shafei M. Postpartum and postabortion intrauterine device insertion unmet needs of safe reproductive health: three year experience of Mansoura University Hospital. Eur J Contracept Reprod Health Care 2000; 26: 253-62.
  13. Grimes D et al. Immediate post - partum insertion of intrauterine devices.[update of Cochrane Datab System Rev, 2001, CD003036; PMID: 11406064]. [Review] [30 refs]. Cochrane Datab System Rev 2003; CD003036.
  14. Morrison C et al. Clinical outcomes of two early postpartum IUD insertion programs in Africa. Contraception 1996; 53: 17-21.
  15. Thiery M et al. The ML Cu250; clinical experience in Belgium and The Netherlands. Brit J Obstet Gynaecol 1982; 89: 51-3.
  16. Thiery M, Delbeke L, Van Kets H. Comparative performance of two copper - wired IUDs (ML Cu 250 and T Cu 200): immediate postpartum and interval insertion. Adv Contracept Deliv Syst 1980; 1: 27-35.
  17. The World Health Organization's Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Intrauterine Devices for Fertility Regulation. The Alza T IPCS 52, a longer acting progesterone IUD: safety and efficacy compared to the TCu22OC and multiload 250 in two randomized multicentre trials. Clin Reprod Fertil 1983; 2: 113-28.
  18. The World Health Organization's Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Intrauterine Devices for Fertility Regulation. IUD insertion following termination of pregnancy: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. Stud Family Plan 1983; 14: 99-108.
  19. The World Health Organization's Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Intrauterine Devices for Fertility Regulation. IUD insertion following spontaneous abortion: a clinical trial of the TCu 220C, Lippes loop D, and copper 7. Stud Fam Plan 1983; 14: 109-14.
  20. El Tagy A et al. Safety and acceptability of post - abortal IUD insertion and the importance of counseling. Contraception 2003; 67: 229-34.
  21. Gillett P.G et al. A comparison of the efficacy and acceptability of the Copper-7 intrauterine device following immediate or delayed insertion after first - trimester therapeutic abortion. Fertil Steril 1980; 34: 121-4.
  22. Grimes D, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices.[update of Cochrane Database Syst Rev. 2000;(2):CD001777; PMID: 10796820]. [Review] [28 refs]. Coch Datab System Rev 2002; CD001777.
  23. Gupta I, Devi P.K. Studies on immediate post - abortion copper "T" device. Ind J Med Res 1975; 63: 736-9.
  24. Moussa A. Evaluation of postabortion IUD insertion in Egyptian women. Contraception 2001; 63: 315-7.
  25. Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel - and copper - releasing intrauterine systems immediately after abortion, with 5 years' follow - up. Contraception 2003; 68: 31-4.
  26. Stanwood N.L, Grimes D.A, Schulz K.F. Insertion of an intrauterine contraceptive device after induced or spontaneous abortion: a review of the evidence. BJOG: Int J Obstet Gynaecol 2001; 108: 1168-73.
  27. Suvisaari J, Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel - releasing intrauterine system. Contraception 1996; 54: 201-8.
  28. Timonen H, Luukkainen T. Immediate postabortion insertion of the copper-T (TCu-200) with eighteen months follow - up. Contraception 1974; 9: 153-60.
  29. Tuveng J.M, Skjeldestad F.E, Iversen T. Postabortal insertion of IUD. Advances in Contraception 1986; 2: 387-92.
  30. Zhang P.Z. Five years experience with the copper T 200 in Shanghai - 856 cases. Contraception 1980; 22: 561-71.
  31. Barrington J.W, Arunkalaivanan A.S, Abdel-Fattah. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol 2003; 108: 72-4.
  32. Hurskainen R et al. Quality of life and cost - effectiveness of levonorgestrel - releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273-7.
  33. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril 2001; 76: 304-9.
  34. Lethaby A.E, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Coch Dat System Rev 2000; CD002126.
  35. Stewart A et al. The effectiveness of the levonorgestrel - releasing intrauterine system in menorrhagia: a systematic review. BJOG: Int J Obstet Gynaecol 2001; 108: 74-86.
  36. Fedele L et al. Use of a levonorgestrel - releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485-8.
  37. Vercellini P et al. A levonorgestrel - releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999; 72: 505-8.
  38. Fedele L et al. Treatment of adenomyosis - associated menorrhagia with a levonorgestrel - releasing intrauterine device. Fertil Steril 1997; 68: 426-9.
  39. Grigorieva V et al. Use of a levonorgestrel - releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003; 79: 1194-8.
  40. Mercorio F et al. The effect of a levonorgestrel - releasing intrauterine device in the treatment of myoma - related menorrhagia. Contraception 2003; 67: 277-80.
  41. Wildemeersch D, Schacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhea with a novel "frameless" intrauterine levonorgestrel - releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001; 6: 192-8.
  42. Wildemeersch D, Schacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel - releasing drug delivery system: a pilot study. Eur J Obstet Gynecol Reprod Biol 2002; 102: 74-9.
  43. Wildemeersch D, Schacht E, Wildemeersch P. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel - releasing drug delivery system: an extended pilot study. Contraception 2002; 66: 93-9.
  44. Wildemeersch D, Schacht E, Wildemeersch P. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women. Maturitas 2003; 44: 237-45.
  45. Larsson B, Wennergren M. Investigation of a copper - intrauterine device (Cu-IUD) for possible effect on frequency and healing of pelvic inflammatory disease. Contraception 1977; 15: 143-9.
  46. Soderberg G, Lindgren S. Influence of an intrauterine device on the course of an acute salpingitis. Contraception 1981; 24: 137-43.
  47. Teisala K. Removal of an intrauterine device and the treatment of acute pelvic inflammatory disease. Ann Med 1989; 21: 63-5.
  48. Faundes A et al. The risk of inadvertent intrauterine device insertion in women carriers of endocervical Chlamydia trachomatis. Contraception 1998; 58: 105-9.
  49. Ferraz do Lago R et al. Follow - up of users of intrauterine device with and without bacterial vaginosis and other cervicovaginal infections. Contraception 2003; 68: 105-9.
  50. Morrison C.S et al. Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device Candidates. Contraception 1999; 59: 97-106.
  51. Pap-Akeson M et al. Genital tract infections associated with the intrauterine contraceptive device can be reduced by inserting the threads into the uterine cavity. Brit J Obstet Gynaecol 1992; 99: 676-9.
  52. Sinei S.K et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Brit J Obst Gynaecol 1990; 97: 412-9.
  53. Skjeldestad F.E et al. IUD users in Norway are at low risk for genital C. trachomatis infection. Contraception 1996; 54: 209-12.
  54. Walsh T.L et al. IUD Study Group. Effect of prophylactic antibiotics on morbidity associated with IUD insertion: results of a pilot randomized controlled trial. Contraception 1994; 50: 319-27.
  55. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992; 304: 809-13.
  56. Carael M et al. Human immunodeficiency virus transmission among heterosexual couples in Central Africa. AIDS 1988; 2: 201-5.
  57. Kapiga S.H et al. Risk factors for HIV infection among women in Dar - es - Salaam, Tanzania. J Acquir Immune Defic Syndr 1994; 7: 301-9.
  58. Kapiga S.H et al. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 1998; 12: 75-84.
  59. Mann J.M et al. HIV infection and associated risk factors in female prostitutes in Kinshasa, Zaire. AIDS 1988; 2: 249-54.
  60. Martin H.L.Jr et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Diseas 1998; 178: 1053-9.
  61. Mati J.K et al. Contraceptive use and the risk of HIV infection in Nairobi, Kenya. Int J Gynaecol Obstet 1995; 48: 61-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2007 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).